Page 1 sur 1

[pubmed] Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the Un

Posté : 24 août 2020 12:00
par RSS-Bot

J Clin Neuromuscul Dis. 2020 Sep;22(1):11-21. doi: 10.1097/CND.0000000000000301.

ABSTRACT

OBJECTIVE: To compare temporal trends in clinical and health care resource utilization (HRU) outcomes in people with refractory and nonrefractory generalized myasthenia gravis (gMG).

METHODS: A retrospective analysis of data from adults with gMG in the Myasthenia Gravis Foundation of America Patient Registry. gMG status (ever-refractory or always nonrefractory) and clinical (Myasthenia Gravis-Activities of Daily Living [MG-ADL] scores, exacerbations) and HRU outcomes were determined from questionnaires self-completed 6-monthly for up to 4 years. The probability of each outcome was compared for the 2 groups over time.

RESULTS: The mean MG-ADL score and the probability of experiencing each outcome were significantly greater in the ever-refractory versus nonrefractory groups during each year of follow-up. Between-group differences in time trends were statistically significant for intensive care and feeding-tube use.

CONCLUSIONS: People who have ever had refractory gMG may have worse functional status, more exacerbations, and higher HRU than people with consistently nonrefractory disease.

PMID:32833720 | DOI:10.1097/CND.0000000000000301


Source: https://pubmed.ncbi.nlm.nih.gov/3283372 ... 2&v=2.11.5